PMID- 32968172
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20210923
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Sep 23
TI  - Landscape of immune checkpoint inhibitor-related adverse events in Chinese 
      population.
PG  - 15567
LID - 10.1038/s41598-020-72649-5 [doi]
LID - 15567
AB  - This study aimed to describe the landscape of Immune checkpoint inhibitors 
      (ICIs)-related adverse events (AEs) in a predominantly Chinese cohort. We 
      searched electronic datasets including PubMed, Web of Science and Embase to 
      identify and recruit relevant trials up to September 2, 2019. Clinical trials 
      focusing on ICIs in Chinese patients or a predominantly Chinese population were 
      included. Incidences of treatment-related AEs (TRAEs) and immune-related AEs 
      (irAEs) were pooled and compared. In total, we recruited 13 trials consisting of 
      1063 patients, with 922 (86.7%) receiving ICI monotherapy and 141 (13.3%) 
      receiving combination of ICI with chemotherapy or anti-angiogenesis. The pooled 
      incidence of any grade TRAEs, grade 1-2, grade 3-5 TRAEs, any grade irAEs, grade 
      1-2 irAEs and grade 3-5 irAEs in all 1063 patients were 84.1%, 63.3%, 20.9%, 
      43.3%, 40.0% and 3.0%, respectively. Moreover, 4.3% (44/1018) of patients 
      experienced treatment discontinuation and only 8 (0.8%) patients experienced 
      treatment-related death. Compared to ICI monotherapy, combination significantly 
      increased grade 3-5 TRAEs (46.1% vs. 17.0%, P < 0.001) and grade 3-5 irAEs (7.1% 
      vs. 2.0%, P = 0.015). By comparing the toxicity profiles between different ICIs, 
      we found some drug-specific AEs such as reactive capillary haemangiomas for 
      camrelizumab (58.6%), hyperglycemia for toripalimab (55.6%) and pyrexia for 
      tislelizumab (54.3%). Additionally, nivolumab has the lowest incidence of any 
      grade (64.1%) and grade 3-5 (11.8%) TRAEs. ICI-related AEs were generally mild 
      and tolerable for a predominantly Chinese cohort. However, we should pay 
      attention to the combination of ICI with chemotherapy as it could increase grade 
      3-5 TRAEs and irAEs.
FAU - Li, Li
AU  - Li L
AD  - Department of Radiation Oncology, Wuzhou Red Cross Hospital, 3-1 Xinxing First 
      Road, Wuzhou, 543001, People's Republic of China.
FAU - Li, Gang
AU  - Li G
AD  - Department of Medical Oncology, Wuzhou Red Cross Hospital, 3-1 Xinxing First 
      Road, Wuzhou, 543001, People's Republic of China.
FAU - Rao, Bin
AU  - Rao B
AD  - Department of Breast Surgery, Wuzhou Red Cross Hospital, 3-1 Xinxing First Road, 
      Wuzhou, 543001, People's Republic of China.
FAU - Dong, An-Hui
AU  - Dong AH
AD  - Department of Breast Surgery, Wuzhou Red Cross Hospital, 3-1 Xinxing First Road, 
      Wuzhou, 543001, People's Republic of China.
FAU - Liang, Wei
AU  - Liang W
AD  - Department of Radiation Oncology, Wuzhou Red Cross Hospital, 3-1 Xinxing First 
      Road, Wuzhou, 543001, People's Republic of China.
FAU - Zhu, Jin-Xian
AU  - Zhu JX
AD  - Department of Radiation Oncology, Wuzhou Red Cross Hospital, 3-1 Xinxing First 
      Road, Wuzhou, 543001, People's Republic of China.
FAU - Qin, Mu-Ping
AU  - Qin MP
AD  - Department of Medical Oncology, Wuzhou Red Cross Hospital, 3-1 Xinxing First 
      Road, Wuzhou, 543001, People's Republic of China.
FAU - Huang, Wen-Wen
AU  - Huang WW
AD  - Department of Breast Surgery, Wuzhou Red Cross Hospital, 3-1 Xinxing First Road, 
      Wuzhou, 543001, People's Republic of China.
FAU - Lu, Jie-Ming
AU  - Lu JM
AD  - Department of Breast Surgery, Wuzhou Red Cross Hospital, 3-1 Xinxing First Road, 
      Wuzhou, 543001, People's Republic of China.
FAU - Li, Zi-Fang
AU  - Li ZF
AD  - Department of Medical Oncology, Wuzhou Red Cross Hospital, 3-1 Xinxing First 
      Road, Wuzhou, 543001, People's Republic of China.
FAU - Wu, Yao-Zhong
AU  - Wu YZ
AD  - Department of Breast Surgery, Wuzhou Red Cross Hospital, 3-1 Xinxing First Road, 
      Wuzhou, 543001, People's Republic of China. wuyaozhongwzhh@163.com.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0KVO411B3N (tislelizumab)
RN  - 31YO63LBSN (Nivolumab)
RN  - 73096E137E (camrelizumab)
RN  - 8JXN261VVA (toripalimab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use
MH  - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - China/epidemiology
MH  - Drug-Related Side Effects and Adverse Reactions/classification/*pathology
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use
MH  - Immunotherapy/adverse effects
MH  - Male
MH  - Neoplasms/*epidemiology/immunology/therapy
MH  - Nivolumab/adverse effects/therapeutic use
PMC - PMC7511303
COIS- The authors declare no competing interests.
EDAT- 2020/09/25 06:00
MHDA- 2020/12/18 06:00
PMCR- 2020/09/23
CRDT- 2020/09/24 05:31
PHST- 2020/01/02 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/09/24 05:31 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/09/23 00:00 [pmc-release]
AID - 10.1038/s41598-020-72649-5 [pii]
AID - 72649 [pii]
AID - 10.1038/s41598-020-72649-5 [doi]
PST - epublish
SO  - Sci Rep. 2020 Sep 23;10(1):15567. doi: 10.1038/s41598-020-72649-5.